3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
2
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
12
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Melanoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HER2 Negative Breast Cancer Not Immediately Operated
1
Glioma
1
Fallopian Tube Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Breast Diseases
1
Anatomic Stage II Breast Cancer AJCC v8
1
Interventions
Carboplatin
46
Paclitaxel
31
pembrolizumab
25
Cyclophosphamide
24
Nivolumab
14
Bevacizumab
14
Topotecan
12
Gemcitabine
12
liposomal doxorubicin
11
Filgrastim
11
Cisplatin
11
fludarabine
10
Peripheral Blood Stem Cell Transplantation
10
olaparib
8
aldesleukin
7
durvalumab
6
Oxaliplatin
6
Ipilimumab
6
Interleukin-2
6
Docetaxel
6
niraparib
5
epacadostat
5
cemiplimab
5
Ifosfamide
5
Fulvestrant
5
rucaparib
4
poly ICLC
4
pazopanib
4
avelumab
4
atezolizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Ovarian Neoplasms
×
ribociclib
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled